Amgen

The subsidiary of Google parent Alphabet plans to use its first round of external funding to boost its artificial-intelligence drug design pipeline across multiple therapeutic areas.

Data from AbbVie and Johnson & Johnson will fine-tune OpenFold3 in a confidentiality-preserving environment, powered by Apheris.

A little over a year ago, a Renton man was told there was only one thing left to decide. Did he want to die at home, or in the hospital? He's still living.

Another company involved in using AI to repurpose failed drugs - as well as drugs that have already been approved - is BioXcel Therapeutics. Unlike Ignota, however, the company focuses on compounds that have already demonstrated safety in prior clinical trials, but have been discontinued by their developers for various other reasons.

A Boston drug discovery company that uses AI has hit unicorn valuation. It uses transformer diffusion models, which its CEO says can "understand the concept of time and how you change, from cradle to grave.

Seeking more efficient drug development, pharmaceutical giants and startups are encouraging AI fluency and in some cases offering training for it.

Beyond speed, AI has also helped reduce costs. Conventional methods required nearly $35,000 per genome analysis, but AI-driven models running on GPUs have lowered the cost to under $2,000, making high-quality genomic research more accessible.

Amazon Web Services ( AMZN) has been increasing its partnerships with health companies to advance AI capabilities in healthcare. In the past year, that has included names like GE Healthcare ( GEHC) and General Catalyst.